Valuation: Spatializer Audio Laboratories, Inc.

Market Cap 63.74L 57.17L 52.24L 47.69L 89.85L 60Cr 92.69L 6.3Cr 2.51Cr 32Cr 2.39Cr 2.34Cr 100.92Cr P/E 2024
-0.28x
P/E 2025 -0.1x
Enterprise Value 16.96L 15.21L 13.9L 12.69L 23.91L 16Cr 24.67L 1.68Cr 66.82L 8.51Cr 63.67L 62.3L 27Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -

Financials

2024 2025
Net sales - -
Net income -95.75L -85.88L -78.49L -71.64L -1.35Cr -90Cr -1.39Cr -9.46Cr -3.77Cr -48Cr -3.59Cr -3.52Cr -151.61Cr -87.72L -78.68L -71.9L -65.64L -1.24Cr -82Cr -1.28Cr -8.67Cr -3.46Cr -44Cr -3.29Cr -3.22Cr -138.9Cr
Net Debt -22.41L -20.1L -18.37L -16.77L -31.59L -21Cr -32.59L -2.21Cr -88.29L -11Cr -84.12L -82.31L -35Cr -46.77L -41.95L -38.34L -35L -65.94L -44Cr -68.02L -4.62Cr -1.84Cr -23Cr -1.76Cr -1.72Cr -74Cr
Logo Spatializer Audio Laboratories, Inc.
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from cannabinoids and taps into its global network of scientists and oncology physicians. The Company is advancing its pipeline of new-generation of naturally occurring and synthetic compounds. It is developing product candidates that target skin-related ailments common among cancer patients, including radiodermatitis, pruritus, rashes and dry skin, as well as indications such as chemotherapy-induced peripheral neuropathy, with future areas of focus that may include depression, pain and anxiety.
Employees
-
Sector
-